Advertisement

Related Videos

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Peter Clark, MA, MD, FRCP: A Payer Perspective

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Advertisement

Advertisement




Jul
19
Today In Oncology
EMERALD-3 Shows Benefit With STRIDE Plus TACE in Hepatocellular Carcinoma
Study Finds Rising Breast Cancer Incidence Across Asian American, Native Hawaiian, and Pacific Islander Groups
Meta-Analysis Highlights Cardiovascular Safety Advantage of Second-Generation BTK Inhibitors
ctDNA Status May Predict Benefit From Adjuvant Chemotherapy After Resection of Colorectal Liver Metastases
Tumor Microenvironment Ecotypes May Explain Differences in Multiple Myeloma Outcomes
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo